GlassScriptPhysician profile
Nabeel M Shabout
NPI 1033160858
$47,070.43
in general payments reported to CMS, 2019-2025
11 companies · $883 in 2025
The $883 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $4,229 · 2021: $45.92 · 2022: $24K · 2023: $27.61 · 2024: $3,616 · 2025: $883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,000 · Travel and Lodging: $900 · Food and Beverage: $626.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,000.00 |
| Travel and Lodging | $899.69 |
| Food and Beverage | $625.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $45,422.95 | 2019-2025 | |
| Davol INC. | $1,344.90 | 2019-2025 | Phasix Mesh |
| Revance Therapeutics, INC. | $119.02 | 2024-2025 | Daxxify |
| Smith+Nephew, INC. | $46.09 | 2022 | |
| Becton, Dickinson and Company | $28.74 | 2024 | Phasix Mesh |
| Abbvie INC. | $27.61 | 2023 | Vraylar |
| Ethicon US, LLC | $20.19 | 2024 | Linx Reflux Management System, Stratafix |
| Pacira Pharmaceuticals Incorporated | $16.40 | 2020 | |
| Covidien LP | $16.26 | 2019 | |
| Tela Bio, INC. | $14.85 | 2020 | |
| Acell, INC. | $13.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nabeel Shabout listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.